Loading clinical trials...
Loading clinical trials...
A Phase 1 First-in-Human Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Conditions
Interventions
HWK-016, MUCIN-16-targeted ADC
Bevacizumab
Locations
12
United States
University of Arkansas - Winthrop P. Rockefeller Cancer Institute
Little Rock, Arkansas, United States
START - Los Angeles
Los Angeles, California, United States
SCRI - Florida Cancer Specialists
Sarasota, Florida, United States
St. Francis Medical Center (OSF Healthcare)
Peoria, Illinois, United States
Karmanos Cancer Center
Detroit, Michigan, United States
Start - Ny
Lake Success, New York, United States
Start Date
March 15, 2026
Primary Completion Date
February 1, 2028
Completion Date
February 1, 2028
Last Updated
March 13, 2026
NCT06340568
NCT03986021
NCT06952504
NCT06257264
NCT06253494
NCT07512141
Lead Sponsor
Whitehawk Therapeutics, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions